News and Announcements
May 13, 2024
Dr. Jennifer Cheng, Founder and CEO of PTM Therapeutics, gave an interview to CEO CFO magazine about the why PTM Therapeutics was founded and the why and how PTM Therapeutics discovers unique disease related post translational modification (PTM) targets for potential therapeutic use.
Jan 24, 2024
PTM Therapeutics’ Founder and CEO Dr. Jennifer Cheng has an Op-Ed article concerning the TRIPS Waiver extension published in The Mercury News as well as The East Bay Times.
Sep 09, 2023
PTM Therapeutics’ Dr. Jennifer Cheng (Founder and CEO) will be presenting at the 2023 Springboard Life Sciences Innovation Showcase on October 23rd in New York City.
Apr 01, 2023
PTM Therapeutics and Dr. Jennifer Cheng (Founder and CEO) is honored to have been selected as the 2023 Life Sciences Program Cohort by Springboard Enterprises.
Feb 01, 2022
PTM Therapeutics is pleased to announce the issuance of US Patent Number 11,230,608 covering compositions of matter (humanized antibodies) and methods of treatment thereof.
This patent represents the foundational patent for PTM Therapeutics and covers its lead antibody, PTM-001, a humanized glycan targeting antibody that is being developed for the treatment of Inflammatory Bowel Disease.
Dec 15, 2020
PTM Thera will be presenting a poster entitled: "Validation of hPTM-001, a Humanized Candidate Therapeutics Antibody for Promoting Mucosal Wound Healing in IBD" at the Crohn's & Colitis Congress on Saturday, January 23, 2021 (2 - 3 p.m. EST)
To view and download poster, please go HERE
Nov 03, 2020
PTM Therapeutics will be presenting an update on the selection of hPTM-001, PTM’s lead humanized antibody with mucosal wound healing MOA, at the 2020 IBD Innovate Conference (Virtual) on November 17-18, 2020
May 09, 2020
MBC Biolabs and AbbVie Announces PTM Therapeutics as one of the two winners of the 2020 AbbVie Golden Ticket.
PTM Therapeutics will receive lab space and other benefits at the Bay Area Life Sciences Incubator MBC Biolabs. PTM Therapeutics will join the MBC community at 930 Brittan Ave in San Carlos, CA.
For more information please see the press release HERE
May 06, 2020
PTM Therapeutics, Inc. named as one of the companies on Renaissance Venture Capital Funds’ Hotlist for Spring 2020.
For more information on PTM Therapeutics, please email contact@ptmthera.com
For more information on Renaissance Venture Capital Funds please visit renvcf.com/investments
Dr. Charles Parkos, Scientific Founder of PTM Therapeutics, ringing the bell at the University of Michigan
Feb 18, 2020
PTM Therapeutics and University of Michigan finalizes the exclusive licensing of PTM-001 with a bell-ringing ceremony.